Immune Imprinting and Implications for COVID-19

Overview

Journal Vaccines (Basel)

Date 2023 Apr 28

PMID 37112787

Authors

Zhiqian Zhou

Julia Barrett

Xuan He

Affiliations

Soon will be listed here.

Abstract

Immunological memory is the key source of protective immunity against pathogens. At the current stage of the COVID-19 pandemic, heterologous combinations of exposure to viral antigens during infection and/or vaccination shape a distinctive immunological memory. Immune imprinting, the downside of memory, might limit the generation of immune response against variant infection or the response to the next-generation vaccines. Here, we review mechanistic basis of immune imprinting by focusing on B cell immunobiology and discuss the extent to which immune imprinting is harmful, as well as its effect on SARS-CoV-2 infection and vaccination.

Citing Articles

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster.

Esen M, Fischer-Herr J, Gabor J, Gaile J, Fleischmann W, Smeenk G Vaccines (Basel). 2024; 12(11).

PMID: 39591190 PMC: 11599021. DOI: 10.3390/vaccines12111288.

Associations between clinical data, vaccination status, antibody responses, and post-COVID-19 symptoms in Thais infected with SARS-CoV-2 Delta and Omicron variants: a 1-year follow-up study.

Khongsiri W, Poolchanuan P, Dulsuk A, Thippornchai N, Phunpang R, Runcharoen C BMC Infect Dis. 2024; 24(1):1116.

PMID: 39375604 PMC: 11460119. DOI: 10.1186/s12879-024-09999-2.

COVID-19 mutations: An overview.

Sarkar M, Madabhavi I World J Methodol. 2024; 14(3):89761.

PMID: 39310238 PMC: 11230071. DOI: 10.5662/wjm.v14.i3.89761.

Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023.

Poukka E, Perala J, Nohynek H, Goebeler S, Auranen K, Leino T Euro Surveill. 2024; 29(37).

PMID: 39268649 PMC: 11395282. DOI: 10.2807/1560-7917.ES.2024.29.37.2300587.

Immunogen characterization reveals an intrinsic hindrance in eliciting neutralizing antibodies against JN.1 variant.

Fan J, Zhang Y, Li S, Li Q, Zi Q, Mou X iScience. 2024; 27(8):110405.

PMID: 39108735 PMC: 11300904. DOI: 10.1016/j.isci.2024.110405.

References

Laidlaw B, Ellebedy A . The germinal centre B cell response to SARS-CoV-2. Nat Rev Immunol. 2021; 22(1):7-18. PMC: 8647067. DOI: 10.1038/s41577-021-00657-1. View

Zhang A, Stacey H, Mullarkey C, Miller M . Original Antigenic Sin: How First Exposure Shapes Lifelong Anti-Influenza Virus Immune Responses. J Immunol. 2019; 202(2):335-340. DOI: 10.4049/jimmunol.1801149. View

Aydillo T, Rombauts A, Stadlbauer D, Aslam S, Abelenda-Alonso G, Escalera A . Immunological imprinting of the antibody response in COVID-19 patients. Nat Commun. 2021; 12(1):3781. PMC: 8213790. DOI: 10.1038/s41467-021-23977-1. View

Cortina-Ceballos B, Godoy-Lozano E, Tellez-Sosa J, Ovilla-Munoz M, Samano-Sanchez H, Aguilar-Salgado A . Longitudinal analysis of the peripheral B cell repertoire reveals unique effects of immunization with a new influenza virus strain. Genome Med. 2015; 7:124. PMC: 4658769. DOI: 10.1186/s13073-015-0239-y. View

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

Lee J, Sutton H, Cottrell C, Phung I, Ozorowski G, Sewall L . Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature. 2022; 609(7929):998-1004. PMC: 9491273. DOI: 10.1038/s41586-022-05216-9. View

Callaway E . Heavily mutated Omicron variant puts scientists on alert. Nature. 2021; 600(7887):21. DOI: 10.1038/d41586-021-03552-w. View

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

Cao Y, Jian F, Yu Y, Song W, Yisimayi A, Wang J . Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022; 614(7948):521-529. PMC: 9931576. DOI: 10.1038/s41586-022-05644-7. View

10.

Ndifon W . A simple mechanistic explanation for original antigenic sin and its alleviation by adjuvants. J R Soc Interface. 2015; 12(112). PMC: 4685838. DOI: 10.1098/rsif.2015.0627. View

11.

Davis-Gardner M, Lai L, Wali B, Samaha H, Solis D, Lee M . Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; 388(2):183-185. PMC: 9812288. DOI: 10.1056/NEJMc2214293. View

12.

Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H . Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature. 2022; 603(7903):919-925. PMC: 8967717. DOI: 10.1038/s41586-022-04466-x. View

13.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

14.

Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L . Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020; 182(1):73-84.e16. PMC: 7231725. DOI: 10.1016/j.cell.2020.05.025. View

15.

Collier A, Miller J, Hachmann N, McMahan K, Liu J, A Bondzie E . Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters. N Engl J Med. 2023; 388(6):565-567. PMC: 9847505. DOI: 10.1056/NEJMc2213948. View

16.

Tregoning J, Flight K, Higham S, Wang Z, Pierce B . Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10):626-636. PMC: 8351583. DOI: 10.1038/s41577-021-00592-1. View

17.

Bowen J, Addetia A, Dang H, Stewart C, Brown J, Sharkey W . Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science. 2022; 377(6608):890-894. PMC: 9348749. DOI: 10.1126/science.abq0203. View

18.

Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani M, Abdulrazzaq N . Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021; 326(1):35-45. PMC: 8156175. DOI: 10.1001/jama.2021.8565. View

19.

Wrammert J, Koutsonanos D, Li G, Edupuganti S, Sui J, Morrissey M . Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011; 208(1):181-93. PMC: 3023136. DOI: 10.1084/jem.20101352. View

20.

Park Y, Pinto D, Walls A, Liu Z, De Marco A, Benigni F . Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science. 2022; 378(6620):619-627. DOI: 10.1126/science.adc9127. View